Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could the air in your living room worsen COPD? a trial puts home sensors to the test

NCT ID NCT07799896

Knowledge-focused Sponsor: Ziekenhuis Oost-Limburg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This pilot study follows 15 adults with COPD who recently left the hospital after a flare-up. Researchers place sensors in their homes to measure air quality, light, noise, and temperature, while participants wear a smartwatch that tracks health data. For one month, participants also answer questionnaires about their symptoms, sleep, and daytime sleepiness. The goal is to see whether continuous home monitoring is practical and whether indoor conditions relate to how patients feel and recover.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Wearable smartwatch and indoor environmental quality sensors
What this could lead to
If it works, this could point toward home monitoring tools that help predict or reduce COPD flare-ups after hospital discharge.
What could go wrong
This is a small pilot study with only 15 participants, so results may not apply broadly. It measures feasibility and correlations, not a treatment, and may not lead to changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provide signed and dated informed consent * Adults older than 18 years of age * Previously diagnosed with COPD according to GOLD guidelines * Hospitalization due to AECOPD * Spend \>50% of time indoor at home * Speak and understand the Dutch language Exclusion Criteria: * Previous diagnosis of asthma * (History of) chronic macrolide use (\> 3 months) * Living in institution or residential care center * Estimated life expectancy of less than 6 months * Not in the possession of a smartphone

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute exacerbation of COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute exacerbation of COPD COPD, chronic obstructive pulmonary disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ziekenhuis Oost-Limburg

    Genk, 3600, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.